DAWNRAYS 2009-- ATTEND TO HEALTH PERSISIT IN CREATION
Pharmaceutical industry stands still amid the global economic downturn since 2008. Some patents of major players will expire in the coming years, bringing opportunities to generic manufacturers. China’s pharmaceutical market is estimated to reach RMB 390 billion by 2013, becoming the third largest in the world.
Dawnrays Pharmaceutical (Holdings), located in Suzhou, China, has been a major player in local Chinese market. It is committed to human health, innovation-based products, and good brand image. Suzhou where the company is headquartered has been one of the economic centers in China’s Yangtze River Delta. The area is well-known for its good understanding of market trend and innovation.
Dawnrays Pharmaceutical (Holdings) Ltd. (HXEx: 02348 ) has 6 subsidiaries: Suzhou Dawnrays Pharmaceuticals, Suzhou Dawnrays Chemical, Shanghai Dawnrays Chemical , Dawnrays Pharma Tech(Nantong), Dawnrays Pharma (Hong Kong), and Guandong Dawnrays Pharmaceutical.
Dawnrays Pharmaceutical (Holdings) Ltd. focuses on the R&D, manufacture, and sales of cef- antibiotics and specialty drugs. Its antibiotics include intermediates, APIs, fixed dose drugs, and its specialty drugs cover anti-allergic, cardiovascular, digestive, urinary, and endocrine drugs in troche, capsules, and granulate forms.
In the section of cef-antibiotics, the company has integrated the production chain of intermediates, APIs, and fixed-dose drugs. It is the first Chinese company that manufactures cef－ products via solvent crystallization. Backed by its advanced technology platform for the synthesis of cephalosporin, the company has formed cef- product line of rich product varieties, complete accessory functions, and adequate capacity potential. The quality of the products reaches leading international standard. Dawnrays has established its presence in the fields of cardiovascular and endocrine drugs. Its Xianshu® (cefoperazone sodium and sulbactam sodium for injection), Xianqin® (ceftriaxone sodium for injection), Amlozen® (Amlodipine Besylate) tablets, and Cecoride® (Cetirizine Hydrochloride ) tablets, have leading market shares.
Business integrity and values are key drivers of success for Dawnrays. High standards of integrity are central to achieving responsible research, sourcing, production, distribution, marketing and sales activities. Dawnrays is dedicated to offering high-quality products. The company never attempts to get orders from the country’s drug procurement system by cutting price at the cost of product quality. In the first half of 2008, a market investigation conducted by China’s National Institute for the Control of Pharmaceutical and Biological Products (NICPBP)found high percentage of substandard cefoperazone sodium in market. NICPBP sent warning letters to local regulatory bodies and producers of unqualified products. However, Dawnrays Pharmaceutical did not receive any warning letter up to the end of the investigation period. The news again reveals Dawnrays’ insistence on high quality and respect for human life.
Dawnrays is committed to improving human health. With social responsibility and preemptive thoughts in mind, it keeps innovation and offers safe and effective products. It is aimed at becoming the top pharmaceutical company in China and contributing to human health.
